Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial - Bidard, FC; Hardy-Bessard, AC; Dalenc, F (Lancet Oncol, 2022)